# Journal for ImmunoTherapy of Cancer

Source: https://onco.cc/journals/jitc/  
OnCo record `jitc` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SITC's fully open-access journal: checkpoint-inhibitor and cell-therapy trials, immune-related toxicity management guidelines and immunotherapy biomarkers.

## Summary

Fully open access, published by BMJ on behalf of the Society for Immunotherapy of Cancer. Publishes phase 1 and 2 immunotherapy trials, SITC clinical practice guidelines on immune-related adverse events and biomarkers, and the SITC annual meeting abstracts. Strong on real-world toxicity and combination strategies.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: JITC; J Immunother Cancer
- Publisher: BMJ Group
- Scope: immunotherapy
- Access: open-access

## Sources

- SITC: https://www.sitcancer.org

## Connected records

- institutions: [Society for Immunotherapy of Cancer](https://onco.cc/institutions/sitc/)
- terms: [Biomarker](https://onco.cc/terms/biomarker/), [Immune checkpoint](https://onco.cc/terms/immune-checkpoint/), [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)
- people: [Ezra E. W. Cohen](https://onco.cc/people/ezra-cohen/), [John Kennedy](https://onco.cc/people/john-kennedy/), [Yoon Seung-kew](https://onco.cc/people/yoon-seung-kew/)
- key papers: [Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial](https://onco.cc/key-papers/paper-durvalumab-endometrial-j-immunother-cancer-2021/), [Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-ck-301-101-jitc-2023/), [Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project](https://onco.cc/key-papers/paper-merino-j-immunother-cancer/), [Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)](https://onco.cc/key-papers/paper-wagner-j-immunother-cancer/), [Phase I trial of CJRB-101 plus pembrolizumab in patients with metastatic non-small cell lung cancer, head and neck squamous cell carcinoma and melanoma](https://onco.cc/key-papers/paper-nct05877430-j-immunother-cancer-2026/), [Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915](https://onco.cc/key-papers/paper-checkmate-915-j-immunother-cancer-2025/), [Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma](https://onco.cc/key-papers/paper-keynote-017-j-immunother-cancer-2021-update/), [TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer](https://onco.cc/key-papers/paper-nct05081609-j-immunother-cancer-2022/), [Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial](https://onco.cc/key-papers/paper-javelin-merkel-200-j-immunother-cancer-2018-update/)

---
JSON: https://onco.cc/api/v1/entities/jitc.json